Skip to main content

Hydropres-25 Side Effects

Generic name: hydrochlorothiazide / reserpine

Note: This document contains side effect information about hydrochlorothiazide / reserpine. Some dosage forms listed on this page may not apply to the brand name Hydropres-25.

Applies to hydrochlorothiazide/reserpine: oral tablet.

Warning

Stand up slowly from a sitting or lying position. Hydrochlorothiazide and reserpine may make you feel dizzy.

Do not stop taking hydrochlorothiazide and reserpine suddenly. Even if you feel better, you need this medication to control your condition. Stopping suddenly could cause severe high blood pressure, anxiety, and other dangerous side effects.

Tell your doctor and dentist that you are taking this medication before having surgery.

If you experience any of the following serious side effects, stop taking hydrochlorothiazide and reserpine and seek emergency medical attention:

Other, less serious side effects may be more likely to occur. Continue to take hydrochlorothiazide and reserpine and talk to your doctor if you experience

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.

For Healthcare Professionals

Applies to hydrochlorothiazide / reserpine: oral tablet.

Psychiatric

The depressive syndrome usually consists of melancholy, loss of self confidence, early morning awakening, loss of libido, and reduced appetite.

A case of reserpine withdrawal psychosis has been reported. This uncommon condition may be due to dopamine receptor supersensitivity, which may develop during chronic reserpine therapy.[Ref]

Psychiatric problems related to reserpine therapy can be serious. Depression occurs in 2% to 28% of patients, is more likely when daily doses exceed 0.5 mg, and can present at any time during therapy. Suicidal ideation has been reported. Reserpine-induced depression is quickly reversible if therapy is withdrawn as soon as the syndrome is recognized, but can persist for several months after drug discontinuation if the syndrome fully develops. Reserpine withdrawal psychosis has been reported.[Ref]

Metabolic

Metabolic side effects are commonly associated with hydrochlorothiazide (HCTZ), especially when doses greater than 50 mg per day are used. Mild hypokalemia (decrease of 0.5 mEq/L) occurs in up to 50%, and may predispose patients to cardiac arrhythmias. Metabolic alkalosis, hyponatremia, hypomagnesemia, hypercalcemia, hyperglycemia, and elevated serum uric acid levels are also relatively common. HCTZ may increase serum cholesterol.[Ref]

Since HCTZ may increase total serum cholesterol by 11%, LDL lipoprotein cholesterol by 12%, and VLDL lipoprotein cholesterol levels by 50%, and may reduce insulin secretion, HCTZ should be used with caution in diabetic patients and in those with hypercholesterolemia.

Hyperuricemia may be an important consideration in patients with a history of gout. Hypophosphatemia and low serum magnesium concentrations may occur, but are usually clinically insignificant except in malnourished patients.[Ref]

Hypersensitivity

A 68-year-old man with a history of myocardial infarction (MI) developed dyspnea, chest tightness, a low grade fever, dizziness, sweating, and vomiting associated with cyanosis, a mild leukocytosis, radiographic evidence of pulmonary edema, clinical evidence of hypovolemia, and respiratory acidosis. MI and infection were ruled out. The patient recovered after restoration of his intravascular volume with saline and albumin. The only precipitating factor per history was the ingestion of HCTZ, which the patient had taken without incident for two years. Rechallenge resulted in recurrent acute pulmonary edema. Other signs of hypersensitivity, such as rash and eosinophilia were absent.[Ref]

Hypersensitivity reactions to HCTZ, manifest as nausea, vomiting, diarrhea, and rash, are reported in less than 1% of patients. Case reports of acute pulmonary edema, interstitial cystitis, and interstitial nephritis, and anaphylaxis are associated with HCTZ.[Ref]

Respiratory

Respiratory side effects including nasal congestion are reported in 8% of patients who are receiving reserpine. Other respiratory system side effects are rare, and include approximately 30 case reports of acute noncardiogenic pulmonary edema associated with HCTZ and less than 10 case reports of bronchospasm associated with reserpine.[Ref]

Rare reports of reserpine-induced bronchospasm are believed to be due to inactivation of beta-adrenergic receptors, which can result in a marked potentiation of the bronchoconstrictive effect of histamine.[Ref]

Nervous system

Nervous system side effects commonly associated with reserpine include sedation, lethargy (different from the psychiatric syndrome of depression), drowsiness, weakness, vertigo, insomnia, or headache in approximately 1% to 5% of patients. While reserpine is used to treat tardive dyskinesia, extrapyramidal movements may worsen upon withdrawal of therapy. A case of CNS hypertension, believed to be due to cerebral edema, is associated with reserpine. A single report of cerebrovascular insufficiency is associated with HCTZ-induced plasma volume contraction.[Ref]

Increased parkinsonian movements upon reserpine withdrawal (as with neuroleptics) may be due to supersensitivity to dopamine as a result of increased dopamine receptors that developed during reserpine therapy.[Ref]

Dermatologic

Dermatologic reactions associated with HCTZ include case reports of erythema annular centrifugum, acute eczematous dermatitis, morbilliform and leukocytoclastic vasculitis. Thiazides may induce phototoxic dermatitis. In addition, a rare, distinct entity with clinical and laboratory features indistinguishable from those of subacute cutaneous lupus erythematosus is associated with HCTZ.[Ref]

A 67-year-old white woman with hypothyroidism, hypercalcemia, depression, and hypertension developed facial erythema, headaches, tremors, confusion, and personality changes associated with a new positive ANA and anti-nRNP, and skin biopsy consistent with lupus erythematosus while taking HCTZ, levothyroxine, and amitriptyline. The eruption resolved upon discontinuation of HCTZ, but she later developed a higher ANA titer associated with symptomatic diffuse interstitial pulmonary infiltrates. She was successfully treated with corticosteroids.[Ref]

Renal

Renal side effects including new or worsened renal insufficiency may occur due to HCTZ-induced intravascular volume depletion. Rare cases of interstitial nephritis are associated with HCTZ.[Ref]

Although HCTZ has been used to treat nephrogenic diabetes insipidus, a case report in which the drug was believed to have caused this condition has been reported.[Ref]

Cardiovascular

A woman with paroxysmal atrial tachycardia developed sinus pauses during reserpine therapy which were reproducible by carotid massage, except when isoproterenol was given. Reserpine is known to increase vagal tone and deplete cardiac catecholamines.

One patient, in a series of 231, had emergent hypertension, stroke, and thyrotoxic crisis. Reserpine 1 mg intramuscularly resulted in a blood pressure drop from 180/100 to an unmeasurable level. The patient recovered after isoproterenol therapy.[Ref]

Cardiovascular side effects include hypotension in 8% and bradycardia (and rare cases of syncope with bradycardia) in 3% of patients. HCTZ-induced hypokalemia and hyponatremia may predispose patients to ventricular ectopy or complete AV heart block. A rare case of paroxysmal atrial tachycardia with block associated with reserpine in a patient who was not taking a digitalis preparation has been reported.[Ref]

Gastrointestinal

Thiazide diuretics may increase serum cholesterol and triglycerides, resulting in increased risk of cholesterol gallstone formation. Reports of bowel strictures associated with thiazide ingestion have been reported in the 1960's, although these patients were on a combination HCTZ-potassium product.[Ref]

Gastrointestinal side effects due to unopposed parasympathetic activity produced by catecholamine depletion may lead to increased gastrointestinal motility and secretory activity. Because of this, new diarrhea or worsening of existing diarrhea or increased salivation are reported in 2% of patients. Increased appetite, abdominal pain, or vomiting are rarely reported. Rare cases of pancreatitis and acute cholecystitis have been associated with HCTZ.[Ref]

Genitourinary

Genitourinary complaints are limited to impotence, reported in approximately 1% of male patients.[Ref]

Immunologic

Immunologic side effects are rare. A single case of angioimmunoblastic lymphadenopathy has been associated with reserpine. In one study of 231 patients who were taking reserpine, only one case of a lupus-like syndrome was recorded. The patient has previously received hydralazine.[Ref]

A 79-year-old woman with hypertension, who was taking reserpine, potassium, HCTZ, and ibuprofen, developed fatigue, anorexia, fever, night sweats, and weight loss. Associated laboratory findings showed anemia, lymphocytosis, thrombocytopenia, IgA kappa paraproteinemia, positive ANA, and a positive Coombs' test. Bone marrow biopsy, lymphangiography, and lymph node biopsy showed bone marrow lymphocytosis, enlarged foamy abdominal lymph nodes with irregular filling, and angioimmunoblastic lymphadenopathy, respectively. Within four days after discontinuation of reserpine (her other medications were continued), the paraprotein level normalized and the platelet count rose. After an additional nine months of prednisone therapy, all signs and symptoms resolved.

A 53-year-old man with hypertension developed nausea, vomiting, diarrhea, and progressive anorexia and weakness associated with scleral icterus, anemia with spherocytosis, dark red urine with proteinuria, bilirubinuria, and hemoglobinuria, and elevated lactic dehydrogenase levels 18 months after beginning HCTZ and methyldopa. Haptoglobin was less than 50 mg per dL. Direct and indirect Coombs tests were positive. The patient died suddenly. Autopsy revealed no obvious cause of death, left ventricular hypertrophy, and mild coronary atherosclerosis.[Ref]

Hematologic

Hematologic side effects are rare. Cases of immune-complex hemolytic anemia, aplastic anemia, and thrombocytopenia have been associated with HCTZ.[Ref]

Endocrine

Endocrinologic problems associated with thiazide diuretics include glucose intolerance and a potentially deleterious effect on the lipid profile. This may be important in some patients with or who are at risk for diabetes or coronary artery disease. Reserpine can induce hyperprolactinemia, resulting in gynecomastia in men, breast engorgement in women, and pseudolactation.[Ref]

A prospective study of 34 patients who received oral thiazide diuretics for 14 years without interruption revealed an increased mean fasting blood glucose level after treatment. Withdrawal of thiazide therapy for seven months in 10 of the patients resulted in mean reductions of 10% in fasting blood glucose and 25% in the 2-hour glucose tolerance test value. A control group was not reported.[Ref]

Musculoskeletal

Musculoskeletal side effects are unusual. Myalgias and chills are occasionally reported during HCTZ-induced diuresis.[Ref]

Oncologic

Oncologic concerns were raised after a large drug surveillance center in Boston reported an association between reserpine, a stimulator of prolactin, and breast cancer in 1974, which was partially, but not completely, confirmed in two similar centers in Europe. A critical review of the these studies elucidated several design flaws. Subsequent, controlled studies failed to show an association between reserpine and an increased incidence of breast carcinoma.[Ref]

References

1. Freis ED. Reserpine in hypertension: present status. Am Fam Physician. 1975;11:120-2.

2. Pfeifer HJ, Greenblatt DK, Koch-Wester J. Clinical toxicity of reserpine in hospitalized patients: a report from the Boston Collaborative Drug Surveillance Program. Am J Med Sci. 1976;271:269-76.

3. Fleishman M. Letter: Reserpine, ECT, and depression. Am J Psychiatry. 1975;132:1088.

4. Lewis WH. Iatrogenic psychotic depressive reaction in hypertensive patients. Am J Psychiatry. 1971;127:1416-7.

5. Sharon E, Paolino JS, Kaplan D. Hematemesis after reserpine for Raynaud's phenomenon. Ann Intern Med. 1972;77:479-80.

6. Blumenthal M, Davis R, Doe RP. Carcinoid syndrome following reserpine therapy in thyrotoxicosis. Arch Intern Med. 1965;116:819-23.

7. Luxenberg J, Feigenbaum LZ. The use of reserpine for elderly hypertensive patients. J Am Geriatr Soc. 1983;31:556-9.

8. Widmer RB. Reserpine: the maligned antihypertensive drug. J Fam Pract. 1985;20:81-3.

9. Kent TA, Wilber RD. Reserpine withdrawal psychosis: the possible role of denervation supersensitivity of receptors. J Nerv Ment Dis. 1982;170:502-4.

10. Gibb WE, Malpas JS, Turner P, White RJ. Comparison of bethanidine, alpha-methyldopa, and reserpine in essential hypertension. Lancet. 1970;2:275-7.

11. Samuels AH, Taylor AJ. Reserpine withdrawal psychosis. Aust N Z J Psychiatry. 1989;23:129-30.

12. Berlant JL. Neuroleptics and reserpine in refractory psychoses. J Clin Psychopharmacol. 1986;6:180-4.

13. Ambrosino SV. Depressive reactions associated with reserpine. N Y State J Med. 1974;74:860-4.

14. Reus VI. Behavioral side effects of medical drugs. Prim Care. 1979;6:283-94.

15. Kirschenbaum HL, Rosenberg JM. What to look out for with guanethidine and reserpine. RN. 1984;47:31-3.

16. Goodwin FK, Bunney WE, Jr. Depressions following reserpine: a reevaluation. Semin Psychiatry. 1971;3:435-48.

17. Papademetriou V, Fletcher R, Khatri IM, Freis ED. Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias. Am J Cardiol. 1983;52:1017-22.

18. Ragnarsson J, Hardarson T, Snorrason SP. Ventricular dysrhythmias in middle-aged hypertensive men treated either with a diuretic agent or a beta-blocker. Acta Med Scand. 1987;221:143-8.

19. Hollifield JW, Slaton PE. Thiazide diuretics, hypokalemia and cardiac arrhythmias. Acta Med Scand Suppl. 1981;647:67-73.

20. Polanska AI, Baron DN. Hyponatraemia associated with hydrochlorothiazide treatment . Br Med J. 1978;1:175-6.

21. Pinnock CA. Hyponatraemia associated with hydrochlorothiazide treatment . Br Med J. 1978;1:48.

22. Byatt CM, Millard PH, Levin GE. Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions. J R Soc Med. 1990;83:704-8.

23. Bain PG, Egner W, Walker PR. Thiazide-induced dilutional hyponatraemia masquerading as subarachnoid haemorrhage . Lancet. 1986;2:634.

24. Benfield GF, Haffner C, Harris P, Stableforth DE. Dilutional hyponatraemia masquerading as subarachnoid haemorrhage in patient on hydrochlorothiazide/amiloride/timolol combined drug . Lancet. 1986;2:341.

25. Klimiuk PS, Davies M, Adams PH. Primary hyperparathyroidism and thiazide diuretics. Postgrad Med J. 1981;57:80-3.

26. Seelig CB. Magnesium deficiency in two hypertensive patient groups. South Med J. 1990;83:739-42.

27. Holland OB, Kuhnert L, Pollard J, Padia M, Anderson RJ, Blomqvist G. Ventricular ectopic activity with diuretic therapy. Am J Hypertens. 1988;1:380-5.

28. Fager G, Berglund G, Bondjers G, Elmfeldt D, Lager I, Olofsson SO, Smith U, Wiklund O. Effects of anti-hypertensive therapy on serum lipoproteins. Treatment with metoprolol, propranolol and hydrochlorothiazide. Artery. 1983;11:283-96.

29. Mouallem M, Friedman E, Shemesh Y, Mayan H, Pauzner R, Farfel Z. Cardiac conduction defects associated with hyponatremia. Clin Cardiol. 1991;14:165-8.

30. Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT. Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up. Lancet. 1982;2:1293-5.

31. Bell DS. Insulin resistance. An often unrecognized problem accompanying chronic medical disorders. Postgrad Med. 1993;93:99-103,.

32. Berlin I. Prazosin, diuretics, and glucose intolerance. Ann Intern Med. 1993;119:860.

33. Hoss DM, Nierenberg DW. Severe shaking chills and fever following hydrochlorothiazide administration. Am J Med. 1988;85:747.

34. Klein MD. Noncardiogenic pulmonary edema following hydrochlorothiazide ingestion. Ann Emerg Med. 1987;16:901-3.

35. Hoegholm A, Rasmussen SW, Kristensen KS. Pulmonary oedema with shock induced by hydrochlorothiazide: a rare side effect mimicking myocardial infarction. Br Heart J. 1990;63:186.

36. Biron P, Dessureault J, Napke E. Acute allergic interstitial pneumonitis induced by hydrochlorothiazide [published erratum appears in Can Med Assoc J 1991 Sep 1;145(5):391]. Can Med Assoc J. 1991;145:28-34.

37. Dorn MR, Walker BK. Noncardiogenic pulmonary edema associated with hydrochlorothiazide therapy. Chest. 1981;79:482-3.

38. Grace AA, Morgan AD, Strickland NH. Hydrochlorothiazide causing unexplained pulmonary oedema. Br J Clin Pract. 1989;43:79-81.

39. Levay ID. Hydrochlorothiazide-induced pulmonary edema. Drug Intell Clin Pharm. 1984;18:238-9.

40. Alted E, Navarro M, Cantalapiedra JA, Alvarez JA, Blasco MA, Nunez A. Non-cardiogenic pulmonary edema after oral ingestion of hydrochlorothiazide . Intensive Care Med. 1987;13:364-5.

41. Applegate WB, Carper ER, Kahn SE, Westbrook L, Linton M, Baker MG, Runyan JW, Jr. Comparison of the use of reserpine versus alpha-methyldopa for second step treatment of hypertension in the elderly. J Am Geriatr Soc. 1985;33:109-15.

42. Segal MS. Bronchospasm after reserpine. N Engl J Med. 1969;281:1426-7.

43. Atuk NO, Owen JA, Jr. Bronchospasm after reserpine. N Engl J Med. 1969;281:908-9.

44. Diamond L. Drug-induced bronchospasm. J Clin Pharmacol J New Drugs. 1970;10:215-6.

45. Bacher NM, Lewis HA. Reserpine and tardive dyskinesia. Am J Psychiatry. 1984;141:719.

46. Dilsaver SC, Greden JF. Possible cholinergic mechanism in reserpine and tardive dyskinesia. Am J Psychiatry. 1984;141:151-2.

47. Peters HA. Questioning reserpine's adverse effect on tardive dyskinesia. Am J Psychiatry. 1983;140:1106.

48. Donatelli A, Geisen L, Feuer E. Case report of adverse effect of reserpine on tardive dyskinesia. Am J Psychiatry. 1983;140:239-40.

49. Murayama M, Yasuda K, Minamori Y, Mercado-Asis LB, Yamakita N, Miura K. Long term follow-up of Cushing's disease treated with reserpine and pituitary irradiation. J Clin Endocrinol Metab. 1992;75:935-42.

50. Ross RT. Drug-induced parkinsonism and other movement disorders. Can J Neurol Sci. 1990;17:155-62.

51. Diffey BL, Langtry J. Phototoxic potential of thiazide diuretics in normal subjects. Arch Dermatol. 1989;125:1355-8.

52. Parodi A, Romagnoli M, Rebora A. Subacute cutaneous lupus erythematosus-like eruption caused by hydrochlorothiazide. Photodermatol. 1989;6:100-2.

53. Goodrich AL, Kohn SR. Hydrochlorothiazide-induced lupus erythematosus: a new variant? J Am Acad Dermatol. 1993;28:1001-2.

54. Fichman MP, Vorherr H, Kleeman CR, Telfer N. Diuretic-induced hyponatremia. Ann Intern Med. 1971;75:853-63.

55. Magil AB, Ballon HS, Cameron EC, Rae A. Acute interstitial nephritis associated with thiazide diuretics. Clinical and pathologic observations in three cases. Am J Med. 1980;69:939-43.

56. Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R. Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy. Can Med Assoc J. 1979;121:591-4.

57. Itescu S, Haskell LP, Tannenberg AM. Thiazide-induced clinically significant hypophosphatemia . Clin Nephrol. 1987;27:161-2.

58. Magil AB. Drug-induced acute interstitial nephritis with granulomas. Hum Pathol. 1983;14:36-41.

59. Delevett AF, Recalde M. Diuretic-induced renal colic. JAMA. 1973;225:992.

60. Kone B, Gimenez L, Watson AJ. Thiazide-induced hyponatremia. South Med J. 1986;79:1456-7.

61. Goette DK, Beatrice E. Erythema annulare centrifugum caused by hydrochlorothiazide-induced interstitial nephritis. Int J Dermatol. 1988;27:129-30.

62. Combs RM. Unusual response to reserpine in paroxysmal atrial tachycardia with block unassociated with digitalis. South Med J. 1967;60:839-42.

63. Dillon PT, Babe J, Meloni CR, Canary JJ. Reserpine in thyrotoxic crisis. N Engl J Med. 1970;283:1020-3.

64. Dietz MW. Iatrogenic jejunal ulcer. Am J Roentgenol Radium Ther Nucl Med. 1967;99:136-8.

65. Reinus FZ, Weinberger HA, Fischer WW. Medication-induced ulceration of the small bowel. Am J Surg. 1966;112:97-101.

66. Wagner W, Longerbeam JK, Smith LL, Feikes HL. Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation. Am Surg. 1967;33:7-11.

67. Uman SJ. Reserpine and Raynaud's phenomenon. Ann Intern Med. 1972;77:1005.

68. Beck ML, Cline JF, Hardman JT, Racela LS, Davis JW. Fatal intravascular immune hemolysis induced by hydrochlorothiazide. Am J Clin Pathol. 1984;81:791-4.

69. Shirey RS, Bartholomew J, Bell W, Pollack B, Kickler TS, Ness PM. Characterization of antibody and selection of alternative drug therapy in hydrochlorothiazide-induced immune hemolytic anemia. Transfusion. 1988;28:70-2.

70. Entrican JH, Denburg JA, Gauldie J, Kelton JG. Angioimmunoblastic lymphadenopathy associated with reserpine. Lancet. 1984;2:820-1.

71. Garratty G, Houston M, Petz LD, Webb M. Acute immune intravascular hemolysis due to hydrochlorothiazide. Am J Clin Pathol. 1981;76:73-8.

72. Eisner EV, Crowell EB. Hydrochlorothiazide-dependent thrombocytopenia due to IgM antibody. JAMA. 1971;215:480-2.

73. Balizet L. Recurrent parathyroid adenoma. Association with prolonged thiazide administration. JAMA. 1973;225:1238-9.

74. Mack TM, Henderson BE, Gerkins VR, et al. Reserpine and breast cancer in a retirement community. N Engl J Med. 1975;292:1366-71.

75. Kodlin D, McCarthy N. Reserpine and breast cancer. Cancer. 1978;41:761-8.

76. Curb JD, Hardy RJ, Labarthe DR, Borhani NO, Taylor JO. Reserpine and breast cancer in the Hypertension Detection and Follow- Up Program. Hypertension. 1982;4:307-11.

77. Labarthe DR, O'Fallon WM. Reserpine and breast cancer. A community-based longitudinal study of 2,000 hypertensive women. JAMA. 1980;243:2304-10.

78. Jick H. Editorial: Reserpine and breast cancer: a perspective. JAMA. 1975;233:896-7.

79. Newball HH, Byar DP. Does reserpine increase prolactin and exacerbate cancer of prostate? Case control study. Urology. 1973;2:525-9.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.